ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
September 07 2021 - 4:01PM
Esperion (NASDAQ: ESPR), the lipid management company, today
announced that it will host an investor webinar on the current
landscape and future directions in the treatment of elevated
cholesterol on Monday, September 13, 2021 at 1:30pm Eastern Time.
This webinar, taking place during National Cholesterol Awareness
Month, will feature an educational discussion with world-renowned
cardiologist Steven Nissen, M.D., from the Cleveland Clinic, which
was recently named the #2 healthcare hospital in the nation and the
#1 hospital for heart care in U.S. News & World Report’s
“2021-22 Best Hospitals” ranking. Dr. Nissen will cover the
strengths and limitations of the current treatment paradigm for
decreasing cardiovascular disease through lowering of
LDL-cholesterol in adults. He will discuss the current landscape,
historical evolution of treatment guidelines, and opportunities to
bridge the gap in patients not served by current medicines.
Additionally, Dr. Nissen will review the role and importance of
cardiovascular outcomes trials in characterizing the potential
benefits of cardiovascular and LDL-cholesterol lowering
medicines.
The event format will be an educational discussion between Dr.
Nissen and the company’s new Chief Medical Officer, Dr. JoAnne
Foody, and will be followed by Q&A.
This webinar is intended for investors only and is not intended
for healthcare professionals or consumers. To register for the
webinar, please click here.
Steven Nissen M.D., is a world-renowned cardiologist, patient
advocate, and researcher with over 35 years of experience as a
practicing physician. Dr. Nissen is Chairman of the Department of
Cardiovascular Medicine at the Cleveland Clinic and Professor of
Medicine at the Cleveland Clinic Lerner College of Medicine at Case
Western Reserve University. Dr. Nissen was Chairman of the Robert
and Suzanne Tomsich Department of Cardiovascular Medicine from 2006
to 2019 after serving nine years as Vice Chairman of the Department
of Cardiology and five years as Medical Director of the Cleveland
Clinic Cardiovascular Coordinating Center (C5), an organization
that directs multicenter clinical trials.
Dr. Nissen is Chief Academic Officer, Sydell and Arnold Miller
Family Heart, Vascular & Thoracic Institute, and holds the
Lewis and Patricia Dickey Chair in Cardiovascular Medicine. He is
heavily involved with the American College of Cardiology (ACC),
serving as President from March 2006 to March 2007, a member of the
ACC Executive Committee from 2004 to 2008, and spending 10 years as
a member of the organization’s Board of Trustees. In addition, Dr.
Nissen has served several terms on the Program Committee for the
ACC Annual Scientific Sessions.
Dr. Nissen served as a member of the CardioRenal Advisory Panel
of the Food and Drug Administration (FDA) for five years and as
chair of the final year of his membership. He continues to serve as
a periodic advisor to several FDA committees as a Special
Government Employee.
ESPERION TherapeuticsESPERION is The Lipid
Management Company. Our goal is lipid management for everybody,
that’s why we work hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs aren’t being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate and resourceful. For more information, please visit
www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding commercialization plans. Any express or
implied statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties that could cause ESPERION's actual results to differ
significantly from those projected, including, without limitation,
the impact of COVID-19 on our business, clinical activities and
results, supply chain, commercial development and launch plans, and
the risks detailed in ESPERION's filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and ESPERION
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Ben Churchbchurch@esperion.com
734-864-6774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024